It’s not yet clear if the new patient death Pfizer reported in Phase II DAYLIGHT study of fordadistrogene movaparvovec is treatment-related
Product Development
Product Development
Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more
Emerging Company Profile
Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery
Regulation
FDA grants priority review to Stealth’s therapy, removing uncertainty over a priority review voucher needed for economic viability in the ultra-rare disease
Management Tracks
Plus: Germany-based Topas taps new CEO, and updates from Quest, Nimbus and more
BioCentury ISSN 1097-7201